We would love to hear your thoughts about our site and services, please take our survey here.
Its a small device to be fair to them - alot smaller than deepverge. I can see it working in some scenarios - the organised user who won't lose the device. But like has been said already, ours will be far cheaper and doesn't require a device to be carried around
ITM Power (AIM: ITM), the energy storage and clean fuel company, is pleased to announce the sale of a 1.4MW electrolyser to Sumitomo Corporation ("Sumitomo"). The deployment will be used as an important reference plant for further sales in Japan through our partnership with Sumitomo.
This will be the first MW scale electrolyser system ITM Power has deployed in Japan. The HGas2SP product will undergo modification to ensure hydrogen supply pressure is below 10 bar in order to comply with Japan's High Pressure Gas Safety Act. ITM Power and Sumitomo are continuing their collaboration in the areas of business development, local compliance and after sale support to ensure a comprehensive green hydrogen offering in Japan.
Mr Hajime Mori, GM Energy Division of Sumitomo Corporation, said: "This is a significant step forward for the Japanese electrolyser market. Sumitomo is participating in several green hydrogen projects in Japan and ITM Power's technology will contribute in scaling up and cost down of these projects in near future."
Dr Graham Cooley, CEO of ITM Power, said: "I am delighted to be able to report tangible progress in Japan. Our partner Sumitomo continues to bring opportunities to ITM Power for evaluation and we are both working to identify synergies within the wider Sumitomo Corporation. This project is an important reference deployment and we look forward to the execution phase of the project and further progress in the important Japanese market."
Mon, 15th Mar 2021 07:00
RNS Number : 1890S
Omega Diagnostics Group PLC
15 March 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
UK Public Sector Contract disclosure
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that a UK Public Sector contract disclosure has been published yesterday in relation to Omega's contract with the Department of Health and Social Care ("DHSC") to provide manufacturing capacity for COVID-19 lateral flow antigen test, announced on 11 February 2021 (RNS: 6952O).
The disclosure can be seen here:
https://www.find-tender.service.gov.uk/Notice/005133-2021?origin=SearchResults&p=1
Omega notes that in this public government disclosure the contract is stated to have an estimated total value of £374 million. The Company notes that under UK Government Public Sector contract disclosure rules this number necessarily represents a maximum of the potential value of the contract and care should be taken not to use this number as an estimate or forecast of the actual likely value of purchase orders to be received by the Company for the production of COVID-19 lateral flow antigen tests. The value of future purchase orders may be substantially less than stated in yesterday's public Government disclosure.
In addition, the Company still awaits confirmation that a COVID-19 lateral flow antigen test has passed the necessary performance evaluation. Accordingly, there are no COVID-19 lateral flow antigen tests that can be manufactured by Omega, on behalf of the Government, at this time.
As soon as the DHSC has access to a test that has successfully passed performance evaluation, it will be licensed to Omega for manufacture. When the test is ready for production Omega expects to receive purchase orders from the DHSC for these tests and, where appropriate, the Company will make further statements given that these production volumes are expected to result in substantial revenue growth for new financial year.
Colin King, Chief Executive Officer of Omega, said:
"Although the disclosed contract value for our agreement with the UK Government is only an estimate of what the total value could be worth, it is very encouraging, and is an indication of the substantial impact on Omega's future performance that such a level of utilisation of our lateral flow test production capacity might have.
"We look forward to receiving notification of which test will be produced under this arrangement and we will update shareholders as these tests move towards production and purchase orders are received."
This includes piloting the regular testing of contacts of people who tested positive for coronavirus in order to find more coronavirus cases and break the chains of transmission, as people who have had close contact with a confirmed positive case are at higher risk than normal of having the virus.
A recent study suggests that regular testing contacts of confirmed cases is an effective way to reduce transmission of COVID-19, and could potentially reduce the need for self-isolation for contacts of positive cases
Extracts taken from website:
How effective is lateral flow antigen testing?
Lateral flow tests can help to drive down the spread of COVID-19.
Lateral flow tests deliver a rapid result, in 30 minutes. They can find positive cases with high levels of virus that are easy to transmit to others, helping to intercept and reduce further infections.
Lateral flow tests used by the UK government go through a rigorous evaluation by the country’s leading scientists. This means they are accurate, reliable and successfully identify those with COVID-19 who don’t show symptoms and could spread the virus without realising.
Lateral flow tests are not being offered in isolation, but alongside a range of other measures to drive down cases and break chains of transmission. See more on this topic on the Public Health England blog.
How sensitive are the tests?
‘Sensitivity’ refers to the proportion of people with COVID-19 that have a positive test.
When a person has low levels of virus in their system, lateral flow tests are less sensitive than some of the other tests we use, such as PCR tests which we mainly use for people with symptoms.
When levels of virus are at their highest and people are most likely to pass on the disease, lateral flow tests can detect the vast majority of cases.
PCR and lateral flow have different roles to play in controlling the virus, so it isn’t helpful to directly compare them in terms of how sensitive they are:
Lateral flow is useful for finding out if a person is infectious now, and able to transmit the virus to others. The level of sensitivity is high enough to detect the vast majority of these cases. Lateral flow testing is less likely to return a positive result outside the infectious window.
PCR is useful for confirming a suspected case of coronavirus, where the person is already self-isolating and is showing symptoms. Higher sensitivity of PCR means it can identify genetic material from COVID-19 even after the active infection has passed.
The different levels of sensitivity are therefore appropriate for the ways they are used.
How lateral flow testing was trialled
The tests underwent a rigorous validation process including evaluations from Public Health England and the University of Oxford. The Medicines and Healthcare products Regulatory Agency (MHRA) provides ongoing regulatory oversight.
Trials were carried out on the tests in a wide range of environments.
Large-scale pilots have also been carried out, including the whole city pilot in Liverpool in November 2020. As a result of the pilot, 897 positive individuals who would not otherwise have known they were infected, tested positive using lateral flow tests.
Pilots and evaluations
We have an ongoing programme of piloting and evaluating other potential uses of lateral flow tests in a number of institutions and workplaces, such as Jaguar Land Rover and John Lewis Partnership.